Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;109(3):339-350.
doi: 10.1007/s00223-020-00672-9. Epub 2020 Feb 13.

Prospects for Therapies in Osteoarthritis

Asim Ghouri  1 , Philip G Conaghan  2   3
Affiliations
Review

Prospects for Therapies in Osteoarthritis

Asim Ghouri et al. Calcif Tissue Int. 2021 Sep.

Abstract

Osteoarthritis (OA) is a chronic, debilitating disease affecting millions of people worldwide. Management of OA involves pharmacological and non-pharmacological approaches. Conventional pharmacological treatments have limited efficacy and are associated with a number of side-effects, restricting the number of patients who can use them. New pharmacological therapies for managing OA are required and a number have been developed targeting different tissues in OA: bone and cartilage, synovium and nerves. However, there has been overall limited success. Disease-modifying osteoarthritis drugs (DMOADs) are a putative class of therapies aimed at improving OA structural pathologies and consequent symptoms. Recent DMOAD studies have demonstrated some promising therapies but also provided new considerations for future trials.

Keywords: Cartilage; DMOAD; Inflammation; Nociceptive pain; Osteoarthritis; Synovitis.

PubMed Disclaimer

Conflict of interest statement

AG reports no conflicts. PGC reports speakers’ bureaus or consultancies for Abbvie, Astra Zeneca, BMS, Centrexion, EMD Serono, Flexion Therapeutics, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Samumed and Stryker.

References

    1. C Global Burden of Disease Study Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England) 2015;386(9995):743–800. doi: 10.1016/S0140-6736(15)60692-4. - DOI - PMC - PubMed
    1. Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin N Am. 2013;39(1):1–19. doi: 10.1016/j.rdc.2012.10.004. - DOI - PMC - PubMed
    1. Salmon JH, et al. Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies. Osteoarthr Cartil. 2016;24(9):1500–1508. doi: 10.1016/j.joca.2016.03.012. - DOI - PubMed
    1. Chen D, et al. Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone Res. 2017;5:16044. doi: 10.1038/boneres.2016.44. - DOI - PMC - PubMed
    1. Yusuf E, et al. Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Ann Rheum Dis. 2011;70(1):60. doi: 10.1136/ard.2010.131904. - DOI - PubMed

Publication types